Takeda Pharmaceutical Company Limited Share Price Sapporo S.E.
Equities
4502
JP3463000004
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,300 JPY | -1.15% | -.--% | +8.18% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.16B 2,139B | Sales 2025 * | 4,108B 26.17B 2,061B | Capitalization | 6,486B 41.32B 3,254B |
---|---|---|---|---|---|
Net income 2024 | 144B 918M 72.27B | Net income 2025 * | 136B 864M 68.08B | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.02B 1,892B | Net Debt 2025 * | 4,204B 26.78B 2,109B | EV / Sales 2025 * | 2.6 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
45.8
x | Employees | - |
Yield 2024 * |
4.55% | Yield 2025 * |
4.61% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 month | +2.63% | ||
3 months | +4.62% | ||
6 months | -2.27% | ||
Current year | +8.18% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 31/03/14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/01/22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 31/05/16 | |
Ian Clark
BRD | Director/Board Member | 62 | 31/12/18 |
Steven Gillis
BRD | Director/Board Member | 71 | 31/12/18 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.02% | 723B | |
+34.28% | 595B | |
-4.19% | 369B | |
+20.27% | 332B | |
+2.79% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.14% | 168B |
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock